Differential crosstalk between the AMPK and PI3K/Akt pathways in breast cancer cells of differing genotypes: Leptin inhibits the effectiveness of AMPK activation

Oncology Reports

Volumn 34, Issue 4, 2015, Pages 1675-1680

  El Masry, Omar S ^a,b,c   Al Sakkaf, Kaltoom ^d   Brown, Barry L ^a   Dobson, Pauline R M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Akt; AMP activated protein kinase; Breast cancer; Leptin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BREAST CANCER CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENOTYPE; MCF 7 CELL LINE; MDA MB 231 CELL LINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T47D CELL LINE; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

AMP-ACTIVATED PROTEIN KINASES; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; LEPTIN; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MICROENVIRONMENT;

EID: 84939173498     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4198     Document Type: Article

References (32)

1. Hardie DG: The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci 117: 5479-5487, 2004.
2. Lizcano JM, Göransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Mäkelä TP, Hardie DG, et al: LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23: 833-843, 2004.
3. Lawlor MA and Alessi DR: PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114: 2903-2910, 2001.
4. Calleja V, Laguerre M, Parker PJ and Larijani B: Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol 7: e17, 2009.
5. Calleja V, Alcor D, Laguerre M, Park J, Vojnovic B, Hemmings BA, Downward J, Parker PJ and Larijani B: Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol 5: e95, 2007.
6. Calleja V, Laguerre M and Larijani B: 3-D structure and dynamics of protein kinase B-new mechanism for the allosteric regulation of an AGC kinase. J Chem Biol 2: 11-25, 2009.
7. Staal SP: Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84: 5034-5037, 1987.
8. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN and Testa JR: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/ threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89: 9267-9271, 1992.
9. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK and Testa JR: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 93: 3636-3641, 1996.
10. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L and Robertson GP: Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64: 7002-7010, 2004.
11. Stål O, Pérez-Tenorio G, Akerberg L, Olsson B, Nordenskjöld B, Skoog L and Rutqvist LE: Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5: R37-R44, 2003.
12. Xu X, Sakon M, Nagano H, Hiraoka N, Yamamoto H, Hayashi N, Dono K, Nakamori S, Umeshita K, Ito Y, et al: Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep 11: 25-32, 2004.
13. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT and Smyrk TC: AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23: 201-205, 2002.
14. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ and Roth RA: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274: 21528-21532, 1999.
15. Houseknecht KL and Spurlock ME: Leptin regulation of lipid homeostasis: dietary and metabolic implications. Nutr Res Rev 16: 83-96, 2003.
16. Myers MG Jr: Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 59: 287-304, 2004.
17. Cirillo D, Rachiglio AM, la Montagna R, Giordano A and Normanno N: Leptin signaling in breast cancer: An overview. J Cell Biochem 105: 956-964, 2008.
18. El-Masry OS, Brown BL and Dobson PR: Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds. Oncol Lett 3: 224-228, 2012.
19. Hardie DG and Alessi DR: LKB1 and AMPK and the cancermetabolism link-ten years after. BMC Biol 11: 36, 2013.
20. Brazil DP, Yang ZZ and Hemmings BA: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29: 233-242, 2004.
21. Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280: 39582-39593, 2005.
22. Kimball SR: Interaction between the AMP-activated protein kinase and mTOR signaling pathways. Med Sci Sports Exerc 38: 1958-1964, 2006.
23. Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B and Menendez JA: The antidiabetic drug metformin: A pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 20: 592-595, 2009.
24. Hadad SM, Fleming S and Thompson AM: Targeting AMPK: A new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 67: 1-7, 2008.
25. Sundaram S, Johnson AR and Makowski L: Obesity, metabolism and the microenvironment: Links to cancer. J Carcinog 12: 19, 2013.
26. Ando S and Catalano S: The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol 8: 263-275, 2011.
27. F rankenberry KA, Skinner H, Somasundar P, McFadden DW and Vona-Davis LC: Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 28: 985-993, 2006.
28. Garofalo C and Surmacz E: Leptin and cancer. J Cell Physiol 207: 12-22, 2006.
29. Okumura M, Yamamoto M, Sakuma H, Kojima T, Maruyama T, Jamali M, Cooper DR and Yasuda K: Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. Biochim Biophys Acta 1592: 107-116, 2002.
30. Perera CN, Spalding HS, Mohammed SI and Camarillo IG: Identification of proteins secreted from leptin stimulated MCF-7 breast cancer cells: A dual proteomic approach. Exp Biol Med (Maywood) 233: 708-720, 2008.
31. Nkhata KJ, Ray A, Schuster TF, Grossmann ME and Cleary MP: Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 21: 1611-1619, 2009.
32. Park J and Scherer PE: Leptin and cancer: From cancer stem cells to metastasis. Endocr Relat Cancer 18: C25-C29, 2011.